1-5 of 5
Lauren Averett Byers
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P079: The impact of BCL2 expression on sensitivity to the novel Aurora kinase B inhibitor AZD2811 in small cell lung cancer

Azusa Tanimoto, Carminia M. Della Corte, Kavya Ramkumar, Robert J. Cardnell, Allison C. Stewart, Carl M. Gay, Lauren Averett Byers, Qi Wang, Li Shen, Jing Wang, Jon Travers
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P079.
https://doi.org/10.1158/1535-7163.TARG-21-P079
Published: 01 December 2021
View article titled, Abstract P079: The impact of BCL2 expression on sensitivity to the novel Aurora kinase B inhibitor AZD2811 in small cell lung cancer
Journal Articles

Abstract C295: Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.

Zev A. Wainberg, Johann S. de Bono, Lida Mina, Jasgit Sachdev, Lauren Averett Byers, Rashmi Chugh, Charlie Zhang, Joshua W. Henshaw, Andrew Dorr, John Glaspy, Ramesh Ramanathan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C295.
https://doi.org/10.1158/1535-7163.TARG-13-C295
Published: 01 November 2013
View article titled, Abstract C295: Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
Journal Articles

Abstract B156: An epithelial to mesenchymal transition (EMT) gene expression signature predicts resistance to PI3K/Akt pathway inhibitors in non-small cell lung cancer.

Lauren Averett Byers, Jing Wang, Lixia Diao, Luc Girard, Michael Peyton, Kevin R. Coombes, John N. Weinstein, Varsha Gandi, Nancy Krett, Steven T. Rosen, John D. Minna, John V. Heymach
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B156.
https://doi.org/10.1158/1535-7163.TARG-11-B156
Published: 12 November 2011
View article titled, Abstract B156: An epithelial to mesenchymal transition (EMT) gene expression signature predicts resistance to PI3K/Akt pathway inhibitors in non-small cell lung cancer.
Journal Articles

Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer

Lauren Averett Byers, F. Christopher Holsinger, Merrill S. Kies, William N. William, Adel K. El-Naggar, J. Jack Lee, Jianhua Hu, Adriana Lopez, Hai T. Tran, Shaoyu Yan, Zhiqiang Du, K. Kian Ang, Bonnie S. Glisson, Maria Gabriela Raso, Ignacio I. Wistuba, Jeffrey N. Myers, Waun-Ki Hong, Vali Papadimitrakopoulou, Scott M. Lippman, John V. Heymach
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1755–1763.
https://doi.org/10.1158/1535-7163.MCT-09-1047
Published: 09 June 2010
View article titled, Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer
Open the PDF for Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer in another window
Journal Articles

Reverse-phase protein array (RPPA) profiling of non-small cell lung cancer lines identifies tumor signatures for sensitivity and resistance to chemotherapy and targeted agents

Lauren Averett Byers, Meera Nanjundan, Luc Girard, Kevin Coombes, Yang Xie, Michael Peyton, Yao Ma, Sunny Zachariah, Petros Nikolinakos, Ricardo Cigarroa, Gordon Mills, Jack Roth, John Minna, John Heymach
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B178.
Published: 01 November 2007
View article titled, Reverse-phase protein array (RPPA) profiling of non-small cell lung cancer lines identifies tumor signatures for sensitivity and resistance to chemotherapy and targeted agents